JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).

Moehler M. H. , Ryu M., Lee K., Coskun H. S. , Wong R., Ozguroglu M. , ...Daha Fazla

Gastrointestinal Cancers Symposium, San-Francisco, Kostarika, 18 - 20 Ocak 2018, cilt.36 identifier